

# SEQUENCE LISTING

<110> Ullrich, Axel  
 Bange, Johannes  
 Knyazev, Pjotr

<120> Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancer

<130> 205884

<140> US 09/600,826  
 <141> 2000-09-07

<150> PCT/EP99/00405  
 <151> 1999-01-22

<150> DE 198 02 377.4  
 <151> 1998-01-22

<160> 8

<170> PatentIn Ver. 2.1

<210> 1  
 <211> 25  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> DOMAIN  
 <222> (1)..(25)  
 <223> amino acid sequence of  
 FGFR-4 (mutant) between positions 366-390

<400> 1  
 Arg Tyr Thr Asp Ile Ile Leu Tyr Ala Ser Gly Ser Leu Ala Leu Ala  
 1 5 10 15  
 Val Leu Leu Leu Leu Ala Arg Leu Tyr  
 20 25

<210> 2  
 <211> 25  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> DOMAIN  
 <222> (1)..(25)  
 <223> amino acid sequence of  
 FGFR-4 (wild-type) between positions 366-390

<400> 2  
 Arg Tyr Thr Asp Ile Ile Leu Tyr Ala Ser Gly Ser Leu Ala Leu Ala  
 1 5 10 15

Val Leu Leu Leu Leu Ala Gly Leu Tyr  
                   20                  25

<210> 3  
 <211> 29  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> PCR primer for the amplification of FGFR-4 (wild-type and mutant)

<400> 3  
 gctcagaggg cgggcggggg tgccggccg 29

<210> 4  
 <211> 33  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> PCR primer for the amplification of FGFR-4 (wild-type and mutant)

<400> 4  
 ccgctcgagt gcctgcacag ccttgagcct tgc 33

<210> 5  
 <211> 24  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> PCR primer for the amplification of the transmembrane domain of FGFR-4  
 (wild-type and mutant)

<400> 5  
 gaccgcagca gcgcccagg ccag 24

<210> 6  
 <211> 23  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> PCR primer for the amplification of the transmembrane domain of FGFR-4  
 (wild-type and mutant)

<400> 6  
 agagggaaga gggagagctt ctg 23

<210> 7  
 <211> 28  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> primer for sequencing of the transmembrane domain of FGFR-4

(wild-type and mutant)

<400> 7

gggaattcga ccgcagcagc gcccgagg

28

<210> 8

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> primer for sequencing of the transmembrane domain of FGFR-4  
(wild-type and mutant)

<400> 8

gctctagaag aggggaagagg gagag

25

## SEQUENCE PROTOCOL

<110> Max-Planck Society for the Promotion of Science e.V., Berlin  
 <120> Use of inhibitors for the treatment of RTK hyperfunction-induced disorders, particularly cancer.

<130> P29374-03166

<140>

<141>

<160> 2

<170> PatentIn Vers. 2.0

<210> 1

<211> 25

<212> PRT

<213> Artificial sequence

<400> 1

Arg	Tyr	Thr	Asp	Ile	Ile	Leu	Tyr	Ala	Ser	Gly	Ser	Leu	Ala	Leu	Ala
1				5				10						15	
Val	Leu	Leu	Leu	Leu	Ala	Arg	Leu	Tyr							
			20					25							

<210> 2

<211> 25

<212> PRT

<213> Artificial sequence

<400> 2

Arg	Tyr	Thr	Asp	Ile	Ile	Leu	Tyr	Ala	Ser	Gly	Ser	Leu	Ala	Leu	Ala
1				5				10						15	
Val	Leu	Leu	Leu	Leu	Ala	Gly	Leu	Tyr							
			20					25							